What is Entacapone?

Entacapone is an international non -mileage name for Comtan, a prescription drug used to treat Parkinson's disease. This is defined as a degenerative disorder of the central nervous system (CNS) commonly associated with a decrease in motor skills that include slow motion and uncontrollable fraying. The Finnish pharmaceutical company Orion Corporation develops the drug. Another pharmaceutical company, Novartis International AG, based in Switzerland, sells it under the Comtan brand.

The term of the Comtans-drawn as Comtan-Post from Entacapone as a catechol-o-methyl transfer (COMT) inhibitor. This means that it prevents the catechol-o-methyltransferase of degrading neurotransmitters such as dopamine, epinephrine and norepinephrine. These substances are sometimes referred to as catecholamines, hormones of the sympathetic nervous system (SNS) that contribute to the regulation of stress response. In particular, dopamine is essential because Parkinson's disease is associated with the death of cells containing dopamIn. According to some scientists, however, entacapone must be combined with Carbidopa/Levodopa, a combination of drugs usually sold under the Sinemet brand. Orion and Novaris produce and launch the drug as Stalevo. The purpose of this combination is to treat at the end of the dose of "wear" of Parkinson's disease, while entacapone helps on carbidopa/levodopa to achieve the brain to increase efficiency.

Entacapone is produced as a tablet of 200 milligrams and is intended for oral administration. Medicines should be taken up to eight times a day and can be used with food or drink or without drinking. People who are planning to use entacapone should tell their doctors whether they are allergic to certain drugs, have or have liver disease or fight alcoholism, plan to have surgery, or have plans for pregnancy.

It is important to realize that entacapone is used to control the symptoms of Parkinson's disease, not to cure. In addition can lEying cause side effects such as diarrhea, dizziness, drowsiness and gastrointestinal problems such as abdominal pain and diarrhea. More serious side effects include breathing problems, confused moods, hallucinations, high fever, muscle stiffness and weakness. Entacapone can also cause urine to turn into a brownish orange color, although it is not considered a harmful sign.

Since April 2011, Entacapon has been an unplanned drug according to the United States Food and Drug Administration (FDA) and drug recovery (DEA). This means that it does not fall into any of the pharmaceutical classifications stipulated by the Act on Controlled Substances, the American drug policy adopted as part of the Act on the Prevention and Control of Drug Abuse. Although it was approved in 2003, the FDA began reviewing in 2010 as a medicine that may increase the risk of developing prostate cancer or cardiovascular diseases.